Evidence mapPaperPMID 36337032Full record

ReviewEuropean heart journal2023

High-density lipoprotein revisited: biological functions and clinical relevance.

Arnold von Eckardstein, Børge G Nordestgaard, Alan T Remaley, Alberico L Catapano

Open access · bronzeAbstract readReview
In one paragraph

Review in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 215 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
215citing papers in PubMed, 5 pooled it
42.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

215 citing papers in PubMed, 5 syntheses or guidelines pooled it, 335 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Effects of aged black garlic (ABG10+Frontiers in nutrition · 2026
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. COPI Coatomer Regulates Several Steps of HDL Metabolism.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

155 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 4 countries.

Arnold von EckardsteinInstitute of Clinical Chemistry, University Hospital Zurich and University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1666-2266
Børge G NordestgaardDepartment of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.ORCID 0000-0002-1954-7220
Alan T RemaleyLipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-5839-7280
Alberico L CatapanoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.ORCID 0000-0002-7593-2094
National Institutes of Health · USUniversity of Copenhagen · DKUniversity of Milan · ITUniversity of Zurich · CH

Funding

Development of Apo Mimetic Peptides for the Treatment Cardiovascular DiseaseZIAHL006095 · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2025 to 2025
$1.6M
6 · The paper itself

Abstract

Previous interest in high-density lipoproteins (HDLs) focused on their possible protective role in atherosclerotic cardiovascular disease (ASCVD). Evidence from genetic studies and randomized trials, however, questioned that the inverse association of HDL-cholesterol (HDL-C) is causal. This review aims to provide an update on the role of HDL in health and disease, also beyond ASCVD. Through evolution from invertebrates, HDLs are the principal lipoproteins, while apolipoprotein B-containing lipoproteins first developed in vertebrates. HDLs transport cholesterol and other lipids between different cells like a reusable ferry, but serve many other functions including communication with cells and the inactivation of biohazards like bacterial lipopolysaccharides. These functions are exerted by entire HDL particles or distinct proteins or lipids carried by HDL rather than by its cholesterol cargo measured as HDL-C. Neither does HDL-C measurement reflect the efficiency of reverse cholesterol transport. Recent studies indicate that functional measures of HDL, notably cholesterol efflux capacity, numbers of HDL particles, or distinct HDL proteins are better predictors of ASCVD events than HDL-C. Low HDL-C levels are related observationally, but also genetically, to increased risks of infectious diseases, death during sepsis, diabetes mellitus, and chronic kidney disease. Additional, but only observational, data indicate associations of low HDL-C with various autoimmune diseases, and cancers, as well as all-cause mortality. Conversely, extremely high HDL-C levels are associated with an increased risk of age-related macular degeneration (also genetically), infectious disease, and all-cause mortality. HDL encompasses dynamic multimolecular and multifunctional lipoproteins that likely emerged during evolution to serve several physiological roles and prevent or heal pathologies beyond ASCVD. For any clinical exploitation of HDL, the indirect marker HDL-C must be replaced by direct biomarkers reflecting the causal role of HDL in the respective disease.

Indexed as

AtherosclerosisLipoproteins, HDLAnimalsCholesterolCholesterol, HDLClinical RelevanceHumansLipoproteinsCholesterolCholesterol, HDLLipoproteinsLipoproteins, HDLAge-related macular degenerationAutoimmune diseaseCancerCholesterol effluxEvolutionInfectious diseaseRemnantsTriglycerides

Identifiers

PMID36337032
PMCPMC10119031
OpenAlexW4308365150

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.